Supplemental Equity and Accumulated Other Comprehensive Income (Loss) Information (Tables)

12 Months Ended

Jun. 30, 2025

Changes in Accumulated other comprehensive income (loss) attributable to Bio-Techne by component (in thousands):


	Unrealized
	Gains		Foreign
	(Losses) on		Currency
	Derivative		Translation
	Instruments		Adjustments		Total
Balance as of June 30, 2022, net of tax	$	8,069	$	(83,269)	$	(75,200)
Other comprehensive income (loss), before tax, attributable to Bio-Techne: :
Amounts before reclassifications ⁽¹⁾		1,340		4,191		5,531
Amounts reclassified out		4,526		152		4,678
Total other comprehensive income (loss), before tax, attributable to Bio-Techne:		5,866		4,343		10,209
Tax expense		(1,073)		—		(1,073)
Total other comprehensive income (loss), net of tax, attributable to Bio-Techne:		4,793		4,343		9,136
Balance as of June 30, 2023, net of tax⁽²⁾	$	12,862	$	(78,926)	$	(66,064)

Other comprehensive income (loss), before tax:
Amounts before reclassifications		(12,632)		(9,941)		(22,573)
Amounts reclassified out		10,317		3,210		13,527
Total other comprehensive income (loss), before tax		(2,315)		(6,731)		(9,046)
Tax expense		(2,445)		(761)		(3,206)
Total other comprehensive income (loss), net of tax		(4,760)		(7,492)		(12,252)
Balance as of June 30, 2024, net of tax⁽²⁾	$	8,102	$	(86,418)	$	(78,316)

Other comprehensive income (loss), before tax:
Amounts before reclassifications		(12,011)		21,895		9,884
Amounts reclassified out		8,448		2,761		11,209
Total other comprehensive income (loss), before tax		(3,563)		24,656		21,093
Tax expense		(2,003)		(654)		(2,657)
Total other comprehensive income (loss), net of tax		(5,566)		24,002		18,436
Balance as of June 30, 2025, net of tax⁽²⁾	$	2,536	$	(62,416)	$	(59,880)

(1)	Amounts before reclassifications related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $33 thousand attributable to the non-controlling interest in Eminence as of June 30, 2023.

(2)	The Company had a net deferred tax liability for its cash flow hedge of $0.8 million, $2.5 million, and $4.0 million as of June 30, 2025, 2024 and 2023.

BIO-TECHNE Corp 10-K